Lenvatinib Mesylate | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Lenvatinib Mesylate
Health Canada Patents

AMI Lifesciences is Driven by Chemistry. Powered by People.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Bhavna Laboratories is an API & Intermediate manufacturer focusing on the muscle relaxant & ophthalmic segments.

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Quotient Sciences- Molecule to Cure. Fast.

Contact Supplier

pharmacompass-2-m-2025-08-25

Lenvatinib Mesylate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

22 API Suppliers, 11 USDMF, 6 EU WC, 4 KDMF, 6 NDC API, 12 Listed Suppliers

22 API Suppliers
11 USDMF
6 EU WC
4 KDMF
6 NDC API
12 Listed Suppliers

DEVELOPMENTS

31 Drugs in Development

31 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

16 FDF Dossiers, 4 FDA Orange Book, 4 Europe, 8 Canada

16 FDF Dossiers
4 FDA Orange Book
4 Europe
8 Canada

DIGITAL CONTENT

12 News #PharmaBuzz

12 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

1 US Medicaid Prescriptions

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

38 US Patents, 8 US Exclusivities, 32 Health Canada Patents

38 US Patents
8 US Exclusivities
32 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

32 All

01 24Eisai Limited

02 8Torys LLP

filter Patent Reset all filters

32 All

01 82426461

02 82543650

03 82652442

04 82771403

filter Product Reset all filters

32 All

01 32LENVATINIB MESYLATE

filter Dosage Reset all filters

32 All

01 32CAPSULE

filter Exp Date Reset all filters

32 All

01 82021-10-19

02 82024-12-22

03 82027-05-17

04 82030-08-16

Product Main Page

01

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2652442

Filing Date : 2007-05-17

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2543650

Filing Date : 2004-12-22

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Torys LLP

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Torys LLP

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2426461

Filing Date : 2001-10-19

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2771403

Filing Date : 2010-08-16

Strength per Unit : 10 mg (1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2652442

Filing Date : 2007-05-17

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2543650

Filing Date : 2004-12-22

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Torys LLP

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Torys LLP

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2426461

Filing Date : 2001-10-19

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2021-10-19

Date Granted : 2011-04-12

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2771403

Filing Date : 2010-08-16

Strength per Unit : 14 mg (1 x 4mg + 1 x 10mg)

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-08-16

Date Granted : 2015-02-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

09

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2652442

Filing Date : 2007-05-17

Strength per Unit : 20 mg (2 x 10mg )

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2027-05-17

Date Granted : 2014-12-09

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

10

Eisai Limited

LENVATINIB MESYLATE

Coatings Trends

Not Confirmed

Eisai Limited

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

LENVATINIB MESYLATE

Brand Name : LENVIMA

Patent Number : 2543650

Filing Date : 2004-12-22

Strength per Unit : 20 mg (2 x 10mg )

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2024-12-22

Date Granted : 2010-10-26

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!